XML 49 R37.htm IDEA: XBRL DOCUMENT v3.23.2
License and Collaboration Agreements - Additional Information (Details) - USD ($)
1 Months Ended 3 Months Ended 6 Months Ended
Feb. 12, 2021
Apr. 03, 2018
Jul. 23, 2017
Apr. 30, 2018
Jun. 30, 2023
Jun. 30, 2022
Jun. 30, 2023
Jun. 30, 2022
Mar. 31, 2022
Dec. 31, 2020
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Derivative liability                 $ 0  
Revenue, excluding assessed tax         $ 20,499,000 $ 21,585,000 $ 42,093,000 $ 46,407,000    
SFJ                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Committed funding (up to) $ 150,000,000                  
Success payments (up to) $ 637,500,000                  
Non-cash royalty revenue related to the sales of future royalties                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Revenue, excluding assessed tax         15,832,000 16,264,000 32,693,000 33,825,000    
Bristol Myers Squibb Company | Purchase Agreement                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Shares issued (in shares)       8,284,600            
Sale of stock consideration received       $ 850,000,000            
Bristol Myers Squibb Company | Nektar 214 | Research and Development Expense                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Reimbursement of expenses           $ 7,600,000   $ 24,900,000    
Other Partner                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Potential future additional payments for development milestones         $ 40,000,000   $ 40,000,000      
Nektar-358 | Eli Lilly                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percentage of sharing in Phase 2 development costs     75.00%              
Nektar-358 | Maximum | Eli Lilly And Company                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Potential future additional development and regulatory milestones (up to)     $ 250,000,000              
Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company | Nektar 214                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percentage of sharing production costs   35.00%                
Bristol Myers Squibb Collaboration Agreement | Bristol Myers Squibb Company | Nektar 214 | Opdivo                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percentage of sharing development costs   67.50%                
Nektar's | Nektar-358                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Received upfront and milestone payment     $ 150,000,000              
Percentage of sharing in Phase 2 development costs     25.00%              
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percentage of sharing production costs   65.00%                
Upfront and milestone payments received from license agreements       $ 1,000,000,000            
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Milestone One                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Potential future additional payments for development milestones                   $ 50,000,000
Nektar's | Bristol Myers Squibb Collaboration Agreement | Nektar 214 | Opdivo                    
Collaborative Arrangements and Non-collaborative Arrangement Transactions [Line Items]                    
Percentage of sharing development costs   32.50%